Top Markets
#1 Derive Derive +30.46%
#2 Cross Cross +14.21%
#3 Audiera Audiera +13.22%
#4 The Bitcoin Bull The Bitcoin Bull +10.65%
#5 Geodnet Geodnet +9.21%
#6 Gama Token Gama Token +9.19%
#7 Velvet Velvet +8.25%
#8 Biconomy Biconomy +8.17%
#9 Fake World Assets Fake World Assets +8.05%
#10 Palladium Network Palladium Network +7.97%
Coin of the day
Derive Derive
設定
言語
日本
通貨
USD
テーマ
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
株式のランク #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
株価
$0.05207079
最終同期: 2023-11-15
時価総額
$3.38M
変化（1日）
0.13%
変化（1年）
0.00%
国
AU
取引 Kazia Therapeutics Limited (KZA)

カテゴリー

Healthcare
Kazia Therapeutics Limited（KZA）の配当利回りの履歴
Kazia Therapeutics Limited（銘柄コード: KZA）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Kazia Therapeutics Limited（KZA）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.48%
BE